Drug-Induced Rhabdomyolysis Secondary To Lenalidomide


  • Himanshu Rathore OSF SAINT Francis Medical Center, Peoria IL, USA
  • Sananjay Singh Faculty of Internal Medicine, University of Illinois, Peoria IL, USA




Rhabdomyolysis, Lenalidomide, Creatine Kinase, Immunomodulatory drugs



Lenalidomide is an immunomodulator imide compound that works through its antitumor, anti-angiogenic, and anti-osteoclastogenic effects. It is increasingly used for a multitude of inflammatory disorders and cancers. Diarrhea, thrombocytopenia, neutropenia, and blood clots are well-established severe side effects of Lenalidomide, but rhabdomyolysis is a rare side effect of the drug. It is difficult to reach this diagnosis because it needs a detailed history of the evolution of symptoms and carefully ruling out other etiologies, especially other drugs. Here we present the case of a 75-year-old female who developed rhabdomyolysis and, subsequently, acute kidney injury after receiving Lenalidomide therapy for multiple myeloma. Discontinuation of the diuretics and the use of isotonic fluids led to a gradual improvement in her condition. Physicians should be aware of this potential rare complication and keep it on the differential when treating patients on Lenalidomide.

Author Biography

Sananjay Singh, Faculty of Internal Medicine, University of Illinois, Peoria IL, USA

Faculty of Internal Medicine




How to Cite

Rathore, H. and Singh, S. (2023) “Drug-Induced Rhabdomyolysis Secondary To Lenalidomide”, International Journal of Integrated Medical Research, 10(01), pp. 01–03. doi: 10.57181/ijoimr/vol10i01/92.